Sol-Gel Technologies (SLGL) Cash & Current Investments (2015 - 2026)
Sol-Gel Technologies (SLGL) posted quarterly Cash & Current Investments of $10.1 million for Q1 2026, down 39.99% year-over-year from $16.9 million in Q1 2025, and down 57.76% quarter-over-quarter from $24.0 million in Q4 2025.
Analysis
Sol-Gel Technologies (SLGL) Cash & Current Investments (2015 - 2026) Analysis & Trends
Sol-Gel Technologies (SLGL) has reported Cash & Current Investments for 11 consecutive years, with $10.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash & Current Investments fell 39.99% year-over-year to $10.1 million; the TTM figure through Mar 2026 stood at $10.1 million (down 39.99% YoY), while the FY2025 annual figure was $24.0 million, down 4.35% from the prior year.
- Cash & Current Investments eased to $10.1 million in Q1 2026 per SLGL's latest filing, from $24.0 million in the prior quarter.
- Across five years, Cash & Current Investments topped out at $42.2 million in Q2 2022 and bottomed at $6.7 million in Q3 2025.
- Historically, Cash & Current Investments has averaged $20.3 million across 5 years, with a median of $21.1 million in 2022.
- On a YoY basis, Cash & Current Investments climbed as much as 68.07% in 2022 and fell as far as 80.39% in 2022.
- Sol-Gel Technologies' Cash & Current Investments stood at $21.1 million in 2022, then soared by 32.46% to $28.0 million in 2023, then decreased by 14.54% to $23.9 million in 2024, then climbed by 0.36% to $24.0 million in 2025, then tumbled by 57.76% to $10.1 million in 2026.
- Business Quant data shows SLGL's Cash & Current Investments at $10.1 million in Q1 2026, $24.0 million in Q4 2025, and $6.7 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 7.99 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 5.18 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 5.14 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 5.10 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 3.31 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 836.99 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 1.16 Bn |
| 10 | Sol-Gel Technologies | 194.01 Mn | 146.08 Mn | - | 47.93 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 47.93 Mn |
| Mar 31, 2026 | 52.83 Mn |
| Dec 31, 2025 | 24.00 Mn |
| Sep 30, 2025 | 6.72 Mn |
| Jun 30, 2025 | 20.68 Mn |
| Mar 31, 2025 | 16.90 Mn |
| Dec 31, 2024 | 23.91 Mn |
| Sep 30, 2024 | 28.05 Mn |
| Jun 30, 2024 | 27.62 Mn |
| Mar 31, 2024 | 16.22 Mn |
| Dec 31, 2023 | 27.98 Mn |
| Sep 30, 2023 | 26.14 Mn |
| Jun 30, 2023 | 30.29 Mn |
| Mar 31, 2023 | 15.31 Mn |
| Dec 31, 2022 | 21.13 Mn |
| Sep 30, 2022 | 25.50 Mn |
| Jun 30, 2022 | 42.24 Mn |
| Mar 31, 2022 | 30.25 Mn |
| Dec 31, 2021 | 21.79 Mn |
| Sep 30, 2021 | 45.59 Mn |